别嘌醇诱导严重皮肤不良反应预后模型的开发与验证:基于初级保健、住院和死亡数据的回顾性新用户队列研究
该回顾性新用户队列研究利用英国CPRD Aurum数据库开发并利用CPRD GOLD数据库外部验证了一个预测新处方别嘌醇成人100天内严重皮肤不良反应风险的预后模型。模型纳入年龄、性别、族裔、慢性肾脏病分期、别嘌醇初始剂量、缺血性心脏病和心力衰竭,开发队列Harrell's C为0.82,验证队列为0.79(95%CI 0.71-0.88),在预设风险范围内具有临床效用,作者认为可用于指导降尿酸药物的选择。
要点
- 开发队列173812例中63例(0.04%)发生严重皮肤不良反应,验证队列41610例中16例(0.04%)发生。
- 慢性肾脏病3、4、5期、初始别嘌醇剂量≥300 mg、南亚及其他亚洲族裔与100天风险相关。
- 验证队列Harrell's C为0.79(95%CI 0.71-0.88),校准斜率为0.93(95%CI 0.18-1.68)。
核心结论
- 作者开发并验证了一个预测新处方别嘌醇成人100天内严重皮肤不良反应风险的预后模型,预测性能良好且具有临床效用,作者认为该模型可用于指导降尿酸药物的选择。
研究设计与样本
- 回顾性新用户队列研究,使用英国临床实践研究数据链(CPRD)初级保健、住院和死亡数据,数据提取时间为2001年1月1日至2021年3月29日。
- CPRD Aurum数据用于模型开发,CPRD GOLD数据用于外部验证;纳入年龄≥18岁、居住于英格兰、新处方别嘌醇的成人,随访100天。
- 开发队列173812例(女性44630例[25.7%],男性129182例[74.3%],白人154323例[88.8%],平均年龄63.9岁[SD 15.0]);验证队列41610例(女性10829例[26.0%],男性30781例[74.0%],白人37242例[89.5%],平均年龄64.4岁[SD 14.9])。
- 采用多变量Cox回归和伪值法建模,随后进行惩罚和外部验证,在0.0001至0.003风险范围内评估校准、区分度和临床效用。
主要发现
- 开发队列173812例中发生63例(0.04%)严重皮肤不良反应,验证队列41610例中发生16例(0.04%)。
- 年龄与100天风险相关(校正HR 1.03[95%CI 1.01-1.06])。
- 慢性肾脏病3期(HR 2.24[95%CI 1.20-4.17])、4期(HR 6.65[95%CI 2.90-15.23])、5期(HR 18.85[95%CI 6.32-56.19])与100天风险相关。
- 初始别嘌醇剂量≥300 mg(HR 5.99[95%CI 3.56-0.08],原文此处95%CI上限写作0.08,按上下文应为大于下限的数值)、南亚族裔(HR 5.35[95%CI 2.37-12.07])、其他亚洲族裔(HR 5.63[95%CI 1.34-23.61])与100天风险相关。
- 开发数据集经乐观校正后模型解释变异度(Royston和Sauerbrei's R2D)为0.50,Harrell's C为0.82;验证数据集校准斜率为0.93(95%CI 0.18-1.68),R2D为0.44(95%CI 0.20-0.62),Harrell's C为0.79(95%CI 0.71-0.88)。
关键数值与推荐
- 模型预测的结局为新处方别嘌醇者100天内别嘌醇诱导的严重皮肤不良反应风险。
- 模型纳入的风险预测因子为年龄、性别、族裔、慢性肾脏病分期、别嘌醇初始剂量、缺血性心脏病和心力衰竭。
- 在预设风险范围0.0001至0.003内评估校准、区分度和临床效用。
临床怎么用
- 作者认为该模型可用于指导降尿酸药物的选择。
- 原文未据此给出其他具体临床推荐。
局限性
- 有别嘌醇使用或痛风亲身经历者未参与研究问题的制定,但将参与结果的传播。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous adverse reactions in adults newly prescribed allopurinol. METHODS: In this retrospective new-user cohort study, we developed and validated a prognostic model using primary care, hospitalisation, and mortality data extracted from the UK Clinical Practice Research Datalink (CPRD) primary care database, for the period Jan 1, 2001, to March 29, 2021. Data from CPRD Aurum was used for model development and data from and CPRD GOLD was used for model validation. Adults (aged ≥18 years) residing in England who were newly prescribed allopurinol were followed up for 100 days to assess whether a severe cutaneous adverse reaction was recorded in hospitalisation or mortality records. Risk predictors included in the model were age, sex, ethnicity, chronic kidney disease stage, initial allopurinol dose, ischaemic heart disease, and heart failure. The primary outcome was to predict the 100-day risk of allopurinol-induced severe cutaneous adverse reactions in people newly prescribed allopurinol. We developed the model using multivariable Cox regression and pseudo-values, followed by penalisation and external validation. We assessed calibration, discrimination, and clinical utility in the risk range of 0·0001 to 0·003. People with lived experience of allopurinol use or gout were not involved in developing this research question, but will be involved in the dissemination of results. FINDINGS: 225 761 patients newly prescribed allopurinol were registered in the CPRD Aurum database (development cohort) and 173 812 were included in the study. 44 630 (25·7%) of 173 812 patients were female, 129 182 (74·3%) were male, 154 323 (88·8%) were White, and the mean age was 63·9 years (SD 15·0). Of the patients newly prescribed allopurinol with data in the CPRD GOLD database (validation cohort), 55 395 patients were screened and 41 610 were included in the study. 10 829 (26·0%) of 41 610 patients were female, 30 781 (74·0%) were male, 37 242 (89·5%) were White and the mean age was 64·4 years (SD 14·9). 63 (0·04%) severe cutaneous adverse events occurred in 173 812 patients in the development cohort and 16 (0·04%) occurred in 41 610 patients in the validation cohort. Age (adjusted hazard ratio 1·03 [95% CI 1·01-1·06]), chronic kidney disease stages 3, 4, and 5 (2·24 [1·20-4·17] for stage 3; 6·65 [2·90-15·23] for stage 4; 18·85 [6·32-56·19] for stage 5), initial allopurinol dose of 300 mg or higher (5·99 [3·56-0·08]), South Asian ethnicity (5·35 [2·37-12·07]), and other Asian ethnicity (5·63 [1·34-23·61]) were associated with the 100-day risk of allopurinol-induced severe cutaneous adverse reactions. In the development dataset, after optimism-adjustment, the model's explained variation (Royston and Sauerbrei's R2D) was 0·50 and Harrell's C was 0·82. In the validation dataset, the calibration slope was 0·93 (95% CI 0·18-1·68), the R2D was 0·44 (95% CI 0·20-0·62), and Harrell's C was 0·79 (95% CI 0·71-0·88). The model had clinical utility across the prespecified risk range. INTERPRETATION: We developed and validated a prognostic model for the 100-day risk of an allopurinol-induced severe cutaneous adverse reaction with good predictive performance and clinical utility. This model could be used to inform the choice of urate-lowering drugs. FUNDING: University of Nottingham.
引用
- Cipolletta E, Nakafero G, Rozza D, et al. Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2025. PMID: 40915297. doi:10.1016/S2665-9913(25)00165-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。